Search
EHA-BMSH joint membership
Save money and time by becoming a joint member of EHA and the Bulgarian Medical Society of Hematology. We've joined forces with the Bulgarian Medical Society of Hematology (BMSH) to offer a special joint membership deal.
Read moreEHA-HSH joint membership
Save money and time by becoming a joint member of EHA and the Hellenic Society of Haematology. We've joined forces with the Hellenic Society of Haematology (HSH) to offer a special joint membership deal.
Read moreEHA-MHTT joint membership
Save money and time by becoming a joint member of EHA and the Magyar Hematológiai és Transzfuziológiai Társaság. We've joined forces with the Magyar Hematológiai és Transzfuziológiai Társaság (MHTT) to offer a special joint membership deal.
Read moreEHA-SFH joint membership
Save money and time by becoming a joint member of EHA and the Société Française d’Hématologie. We've joined forces with the Société Française d’Hématologie (SFH) to offer a special joint membership deal.
Read moreEHA-SPH joint membership
Save money and time by becoming a joint member of EHA and the Sociedade Portuguesa de Hematologia. We've joined forces with the Sociedade Portuguesa de Hematologia (SPH) to offer a special joint membership deal.
Read moreEHA-SRH joint membership
Save money and time by becoming a joint member of EHA and the Societatea Română de Hematologie. We've joined forces with the Societatea Română de Hematologie (SRH) to offer a special joint membership deal.
Read moreEHA-THD joint membership
Save money and time by becoming a joint member of EHA and the Türk Hematoloji Derneği. We've joined forces with the Türk Hematoloji Derneği (THD) to offer a special joint membership deal.
Read moreAdding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years
ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.
Read moreParticipation grants & abstract awards
Participation grants
The call for participation grant applications has closed on March 1, 2021 (23:59 CET). Participation grant application has closed
Participation Grants (previously called Travel Grants) provide complimentary registration for the upcoming EHA Virtual Congress.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- »